13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03266965 (ClinicalTrials.gov) | March 23, 2018 | 4/7/2017 | Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach | Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach | Multiple Sclerosis | Drug: Carbidopa;Dietary Supplement: L-Histidine | University of Miami | United States Department of Defense | Completed | 18 Years | 60 Years | All | 18 | Phase 1 | United States |